Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak
NEW YORK, April 3 (Bernama-BUSINESS WIRE) — Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, ethical choices, effectiveness of government responses, and much more. Multiple study waves including a deeper dive into treatments will be conducted over the next several weeks. To view results and countries visit sermo.com.
http://mrem.bernama.com/viewsm.php?idm=37096
